诺和诺德Novo Nordisk (NVO) 2007年年度报告「NYSE」.pdf

1、Novo Nordisk A/SAnnual Report 2007united to change diabetes financial,social and environmental performance 2007Performance highlights 200720072006ChangeFinancial performanceSales totalDKK million41,83138,7438.0%Diabetes care DKK million30,47827,8669.4%Of which modern insulinsDKK million14,00810,8252

2、9.4%BiopharmaceuticalsDKK million11,35310,8774.4%Gross profitDKK million32,03829,1589.9%Gross margin%76.675.3Sales and distribution costs%of sales29.630.0Research and development costs%of sales20.416.3Research and development costs excl AERx*)%of sales17.216.3Administration expenses%of sales6.06.2Op

3、erating profitDKK million8,9429,119(1.9%)Operating profit excl AERx*)DKK million10,2679,11912.6%Net profitDKK million8,5226,45232.1%Effective tax rate%22.329.6Capital expenditureDKK million2,2682,787(18.6%)Free cash flowDKK million9,0124,70791.5%Long-term financial targetsOperating profit growth%(1.

4、9)12.7Operating profit growth excl AERx*)%12.612.7Operating margin%21.423.5Operating margin excl AERx*)%24.523.5Return on invested capital(ROIC)%27.225.8Cash to earnings%105.773.0Cash to earnings excl AERx*)%94.273.0Non-financial performanceEmployeesFTE25,51623,17210%Engaging culture(employee engage

5、ment)Scale154.14.0Employee turnover%11.610.0Employment impact Number of jobs81,60082,700(1%)CO2emissions1,000 tons2362293%Water consumption1,000 m33,2312,9958%Recycling of waste%3835New patent families(first filing)Number116149(22%)Share performanceDividend per share(proposed)*)DKK4.503.5028.6%Closi

6、ng share price(B shares)*)DKK33523641.9%Market capitalisation(B shares)*)DKK billion17212438.7%*)Excluding non-recurring costs related to discontinuation of the development of the AERxinhaled insulin system.*)Novo Nordisk B shares were split on 3 December 2007and ADRs were split on17 December 2007.*